|Bid||128.36 x 800|
|Ask||128.36 x 800|
|Day's Range||127.85 - 130.15|
|52 Week Range||121.00 - 148.99|
|Beta (3Y Monthly)||0.76|
|PE Ratio (TTM)||21.34|
|Earnings Date||Oct 15, 2019|
|Forward Dividend & Yield||3.80 (2.92%)|
|1y Target Est||149.28|
Johnson & Johnson is still in hot water as the company continues to face thousands of lawsuits over the safety of its baby powder products. Yahoo Finance's Julie Hyman, Adam Shapiro, Brian Sozzi, and Sibile Marcellus discuss.
C ongo's health minister resigned on Monday after being stripped of responsibility for managing the country's Ebola outbreak, potentially paving the way for the introduction of a second vaccine to contain the spreading epidemic. Oly Ilunga has overseen Democratic Republic of Congo's near year-long response to what is the second deadliest Ebola outbreak in history. President Felix Tshisekedi on Saturday appointed a team led by Jean-Jacques Muyembe, the head of Congo's biomedical research institute, to coordinate the government's response in Ilunga's place.
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Many working women hoping to reach feeder positions for CEO still aren’t sure how to advance in their careers, don’t realize the importance of networking and mentorship, have too few role models in senior positions, and too seldom work at companies that actually prioritize advancing women, according to quantitative and qualitative research from the Working Mother Research Institute. Some 25% of chief executive officer, chief financial officer, chief information or technology officer, chief marketing officer and chief human resources officer positions are held by women, according to a 2019 analysis by Korn Ferry, up two percentage points from 2018. Many women are less likely to have a clear sense of how to get ahead compared to their male colleagues, the Working Mother Research Institute study found.
Benzinga has examined prospects for many investor favorite stocks over the past week. Bullish calls included leaders in the aerospace, media and retail sectors. Some bearish calls were prompted by quarterly ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $417 million award to one California plaintiff in August 2017 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
Canaccord Genuity analyst Jason Mills maintained a Buy rating on Intuitive Surgical and lifted the price target from $575 to $610. Stifel analyst Rick Wise rates the shares a Buy, with a $570 price target. Morgan Stanley analyst David Lewis reiterated an Overweight rating and $620 price target.
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.
Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.
JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology. Penumbra works in stroke treatment.
FlexShares, a major purveyor of smart beta exchange traded funds, is throwing its weight around in the low volatility ETF arena in a big way with the introduction of three funds that combine that investment ...